Financials

	2024	2025
Net sales	4.05Cr 4.66Cr 3.77Cr 3.46Cr 6.53Cr 444.61Cr 6.64Cr 44Cr 17Cr 221.35Cr 17Cr 17Cr 742.21Cr	4.11Cr 4.73Cr 3.83Cr 3.51Cr 6.63Cr 451.32Cr 6.74Cr 45Cr 18Cr 224.69Cr 18Cr 17Cr 753.41Cr
Net income	71.55L 82.3L 66.59L 61.14L 1.15Cr 79Cr 1.17Cr 7.85Cr 3.08Cr 39Cr 3.09Cr 3.02Cr 131.15Cr	47.82L 55.02L 44.51L 40.87L 77.18L 53Cr 78.37L 5.25Cr 2.06Cr 26Cr 2.07Cr 2.02Cr 88Cr
Net Debt	-1.73Cr -1.98Cr -1.61Cr -1.47Cr -2.78Cr -189.46Cr -2.83Cr -19Cr -7.43Cr -94Cr -7.45Cr -7.29Cr -316.28Cr	-2.1Cr -2.42Cr -1.96Cr -1.8Cr -3.39Cr -230.99Cr -3.45Cr -23Cr -9.06Cr -115Cr -9.09Cr -8.89Cr -385.6Cr

Company Profile

Eurofins Cerep specializes in the pre-clinical research of drugs for the pharmaceutical industry. Export accounts for 88.2% of net sales.

Employees

Sector

Market Cap	8.22Cr 9.46Cr 7.65Cr 7.03Cr 13Cr 902.85Cr 13Cr 90Cr 35Cr 449.48Cr 36Cr 35Cr 1.51TCr	P/E 2024 *	-	P/E 2025	-
Enterprise Value	6.12Cr 7.04Cr 5.69Cr 5.23Cr 9.87Cr 671.86Cr 10Cr 67Cr 26Cr 334.48Cr 26Cr 26Cr 1.12TCr	EV / Sales 2024	2.02x	EV / Sales 2025	1.67x
Free-Float	4.22%	Yield 2024 *	-	Yield 2025	-

30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/25/02	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
30/23/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/22/30	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI
12/22/12	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Global markets live: Daimler, GSK, Mattel
23/20/23	Eurofins Cerep : Launches PCR COVID-19 Self-Test In Germany, Spain	MT
24/20/24	Eurofins-Cerep Sa Reports Earnings Results for the Half Year Ended June 30, 2020	CI
30/18/30	Eurofins Cerep SA acquired KVI-Plusz.	CI
03/15/03	Eurofins Cerep SA and Jean-Louis Oger, along with the members of the current leadership of Bioaccess, completed the acquisition of a majority stake in Bioaccess S.A.	CI

18/25/18	Eurofins Cerep : annonce ses résultats du 1er semestre 2025	PU
13/23/13	Eurofins Cerep : annonce ses résultats 2022	PU

10/04	Eurofins Cerep : annonce ses résultats 2025
01/25/01	Eurofins Cerep : Rapport Financier Semestriel - Semestre clos le 30 juin 2025
09/25/09	Eurofins Cerep : Rapport annuel 2024
04/25/04	Eurofins Cerep : annonce ses résultats du 1er semestre 2023
04/25/04	Eurofins Cerep : annonce ses résultats 2024

Director	Title	Age	Since
Paul Ratcliffe CHM	Chairman	-	11/08/2023
Damien Vielliard BRD	Director/Board Member	-	23/05/2024
Rodolphe Simonot BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EUROFINS-CEREP	+0.01%	+4,900.50%	-	-	9.46Cr
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+12.94%	4.85TCr
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+411.96%	+472.09%	3.99TCr
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+28.81%	+7.27%	3.87TCr
BEONE MEDICINES AG	-1.88%	-3.03%	+5.69%	+66.52%	3.51TCr
CELLTRION, INC.	-1.74%	+5.12%	+14.44%	+44.64%	2.98TCr
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+36.40%	+126.06%	1.61TCr
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	1.61TCr
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+3.40%	+14.79%	1.36TCr
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-1.73%	-34.97%	1.26TCr
Average	-1.35%	+1.05%	+62.16%	+88.67%	2.78TCr
Weighted average by Cap.	-1.60%	+2.03%	+79.78%	+107.48%